Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV® Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launches R&D expenditures increase by 14.2% to EUR 5.8 bn Boehringer Ingelheim today announced a strong …